Direkt zum Inhalt
Merck

R0654

Sigma-Aldrich

Reveromycin A

solid, suitable for cell culture, BioReagent

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C36H52O11
CAS-Nummer:
Molekulargewicht:
660.79
MDL-Nummer:
UNSPSC-Code:
12352207
PubChem Substanz-ID:
NACRES:
NA.76
Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Produktbezeichnung

Reveromycin A, solid

Biologische Quelle

Streptomyces sp.

Qualitätsniveau

Form

solid

Mol-Gew.

660.79 g/mol

Verpackung

pkg of 100 μg

Farbe

tan

Löslichkeit

DMF: soluble
DMSO: soluble
ethanol: soluble
ethyl acetate: soluble
methanol: soluble
soluble

Wirkungsspektrum von Antibiotika

fungi

Wirkungsweise

protein synthesis | interferes

Versandbedingung

wet ice

Lagertemp.

−20°C

SMILES String

[H][C@]1(C\C=C(C)\C=C\[C@H](O)[C@@H](C)\C=C\C(O)=O)O[C@]2(CC[C@@H]1C)CC[C@@](CCCC)(OC(=O)CCC(O)=O)[C@@]([H])(O2)\C=C\C(C)=C\C(O)=O

InChI

1S/C36H52O11/c1-6-7-19-35(47-34(44)17-16-32(40)41)21-22-36(46-30(35)14-10-25(3)23-33(42)43)20-18-27(5)29(45-36)13-9-24(2)8-12-28(37)26(4)11-15-31(38)39/h8-12,14-15,23,26-30,37H,6-7,13,16-22H2,1-5H3,(H,38,39)(H,40,41)(H,42,43)/b12-8+,14-10+,15-11+,24-9+,25-23+/t26-,27-,28-,29+,30-,35+,36-/m0/s1

InChIKey

ZESGNAJSBDILTB-OXVOKJAASA-N

Biochem./physiol. Wirkung

It is an epidermal growth factor (EGF) and eukaryotic cell growth inhibitor.[1][2]
Reveromycin A is a polyketide antibiotic from Streptomyces sp. Epidermal growth factor (EGF) inhibitor; apoptosis inducer; G1 phase cell cycle inhibitor having antiproliferative behavior against human cell lines KB and K562 as well as antifungal activity.

Hinweis zur Analyse

Avoid acidic conditions.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Hiroaki Muguruma et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11(24 Pt 1), 8822-8828 (2005-12-20)
The purpose of this study was to determine therapeutic effect of a novel antibiotic, reveromycin A, against osteolytic bone metastasis of human small cell lung cancer (SBC-5) cells. Reveromycin A induced apoptosis specifically in osteoclasts in vitro. Although reveromycin A
M Tanaka et al.
Journal of dental research, 91(8), 771-776 (2012-06-08)
In osteoprotegerin-deficient (OPG-/-) mice, osteoclast activity causes bone resorption to outpace bone formation, leading to the development of severe osteoporosis. Such mice are therefore useful for investigating the alveolar bone of patients with osteoporosis. Reveromycin A (RM-A) was recently identified
Shunji Takahashi et al.
Nature chemical biology, 7(7), 461-468 (2011-06-07)
Spiroacetal compounds are ubiquitous in nature, and their stereospecific structures are responsible for diverse pharmaceutical activities. Elucidation of the biosynthetic mechanisms that are involved in spiroacetal formation will open the door to efficient generation of stereospecific structures that are otherwise
Mariana El Sous et al.
Organic letters, 6(17), 3001-3004 (2004-08-28)
The asymmetric total synthesis of (-)-reveromycin A is described. The key steps involved a Lewis acid catalyzed inverse electron demand hetero-Diels-Alder reaction followed by hydroboration/oxidation to afford the spiroketal core 4 in a highly stereoselective manner and introduction of the
H Koshino et al.
The Journal of antibiotics, 45(9), 1420-1427 (1992-09-01)
Reveromycins A, B, C and D are new group inhibitors of the mitogenic activity of epidermal growth factor (EGF), produced by Streptomyces sp. Reveromycins are novel polyketide type antibiotics which have two terminal carboxylic groups, a spiroketal, a succinate and

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.